StratDeckEarly access
UCB
UCB.BRHealthcare · Biotechnology · BE205.20EUR+0.29%
StratDeckUCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
Price · Past year
Loading chart…
Checks
- Fail: Price trending down The figures
- Pass: Sales growing faster than its peers The figures
- Pass: More profitable than similar companies The figures
- Pass: Analysts rate it a buy The figures
- Fail: Costs more than similar companies The figures
- Not known: Last quarter's profit forecast not available
Share
Keep researching
Where next from UCB.BR
Other stocks you may like
Fundamentals
Yahoo FinanceShowHide
Market cap46.8B
P/E19.3×
Forward P/E15.9×
Price / book3.58
Dividend yield0.71%
Revenue YoY+22.50%
EPS YoY+134.80%
Net margin25.7%
Return on equity20.6%
Beta0.40
52-week range197.45–289.508/100
Worst fall in a year-30.7%
ADV (USD)58.2M
10d avg volume246K
What's happening?
UCB.BR is lagging Healthcare this month The figures
- 1D
- +0.29%
- 7D
- +0.64%
- 1M
- -1.39%
- 3M
- -13.78%
- 6M
- -20.27%
- YTD
- -13.46%
What is the market expecting?
StratDeckCosts more than similar companies, and analysts expect the price to rise The figures
AnalystsBuy19
Value score vs Healthcare peers
50- Fwd P/E15.954
- P/B3.651
- Yield0.7%21
- P/E19.377
- Rev growth+22.5%91
Is the business delivering?
Sales are growing faster than at similar companies, and profit per share is up The figures
Earnings by half-year
Latest half-year 0.82 · -0.58 on the half-year before
- 1.40Oct18—
- 0.82Jul21-0.58
How does it compare?
Nearest in Healthcare on valueStratDeckUCB.BR is worse value than most Healthcare stocks The figures
What happens next?
Reports next on 25 Feb, in 127 days
Daily market updates
Get the brief
Get an interesting stock pick, updates on the AI sector, information on the biggest movers of the day, and more, in the Monday, Wednesday and Friday email.